Roflumilast in COPD: a Brazilian perspective.
作者信息
Stirbulov Roberto, Jardim José R
机构信息
Department of Respiratory Diseases, Santa Casa School of Medical Sciences in São Paulo, Federal University of São Paulo, HospitalSão Paulo, São Paulo, Brazil.
Departmentof Respiratory Diseases, Escola Paulista de Medicina, Federal University of São Paulo, HospitalSão Paulo, São Paulo, Brazil.
出版信息
Int J Chron Obstruct Pulmon Dis. 2015 Sep 8;10:1853-5. doi: 10.2147/COPD.S64455. eCollection 2015.
Abstract
摘要
相似文献
1
Roflumilast in COPD: a Brazilian perspective.罗氟司特治疗慢性阻塞性肺疾病：巴西视角
Int J Chron Obstruct Pulmon Dis. 2015 Sep 8;10:1853-5. doi: 10.2147/COPD.S64455. eCollection 2015.
2
Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.罗氟司特对慢性阻塞性肺疾病（COPD）急性加重、医疗保健利用及成本的影响：以老年医保优势人群为主的研究
Int J Chron Obstruct Pulmon Dis. 2015 Mar 16;10:565-76. doi: 10.2147/COPD.S79025. eCollection 2015.
3
[Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany].[罗氟司特联合长效支气管扩张剂用于重度和极重度慢性阻塞性肺疾病患者的管理。德国的成本效益分析]
Dtsch Med Wochenschr. 2013 Jan;138(4):119-25. doi: 10.1055/s-0032-1327416. Epub 2013 Jan 15.
4
Phenotype/endotype-driven therapy in COPD: potential economic implications.慢性阻塞性肺疾病中基于表型/内型的治疗：潜在的经济影响
Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):421-3. doi: 10.1586/14737167.2013.815402.
5
A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.一项关于罗氟司特对现实世界中慢性阻塞性肺疾病患者病情加重及经济负担影响的纵向回顾性队列研究。
Int J Chron Obstruct Pulmon Dis. 2015 Oct 7;10:2127-36. doi: 10.2147/COPD.S80106. eCollection 2015.
6
Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.罗氟司特/噻托溴铵联合治疗与噻托溴铵单药治疗重度至极重度 COPD 的成本效果分析。
J Med Econ. 2011;14(6):805-15. doi: 10.3111/13696998.2011.623204. Epub 2011 Oct 12.
7
A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.罗氟司特治疗重度慢性阻塞性肺疾病患者的1年前瞻性成本效益分析。
Pharmacoeconomics. 2007;25(8):695-711. doi: 10.2165/00019053-200725080-00007.
8
Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.在英国，罗氟司特作为长效支气管扩张剂的附加治疗用于治疗与慢性支气管炎相关的慢性阻塞性肺疾病的成本效益。
Eur J Health Econ. 2014 Jan;15(1):69-82. doi: 10.1007/s10198-013-0456-5. Epub 2013 Feb 8.
9
Roflumilast: Who Is Using It and How It Affects Health Care Resource Utilization and Costs.罗氟司特：哪些人在使用它以及它如何影响医疗资源利用和成本。
Manag Care. 2015 Aug;24(8):40-8.
10
Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.减轻疾病负担并改善肺功能——罗氟司特：获批用于中重度慢性阻塞性肺疾病：临床护理专家的最新资讯
Clin Nurse Spec. 2011 Jul-Aug;25(4):176-7. doi: 10.1097/NUR.0b013e31822229a9.
本文引用的文献
1
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.罗氟司特对联合治疗控制不佳的重度慢性阻塞性肺疾病患者加重的影响（REACT）：一项多中心随机对照试验。
Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13.
2
Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.罗氟司特治疗稳定期慢性阻塞性肺疾病患者的疗效和安全性：一项荟萃分析。
Pulm Pharmacol Ther. 2014 Feb;27(1):83-9. doi: 10.1016/j.pupt.2013.04.004. Epub 2013 Apr 23.
3
Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality.慢性阻塞性肺疾病的长期自然史：严重加重和死亡率。
Thorax. 2012 Nov;67(11):957-63. doi: 10.1136/thoraxjnl-2011-201518. Epub 2012 Jun 8.
4
The use of roflumilast in COPD: a primary care perspective.罗氟司特在慢性阻塞性肺疾病中的应用：基层医疗视角
Prim Care Respir J. 2010 Dec;19(4):342-51. doi: 10.4104/pcrj.2010.00066.
5
Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care.在初级保健中使用数据的综合分析：COPD 患者主要合并症的患病率与心肌梗死和中风的发生率。
Thorax. 2010 Nov;65(11):956-62. doi: 10.1136/thx.2009.128082. Epub 2010 Sep 25.
6
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).慢性阻塞性肺疾病是心肌梗死患者死亡的独立预测因素，但不是动脉粥样硬化事件的预测因素：缬沙坦急性心肌梗死试验（VALIANT）分析。
Eur J Heart Fail. 2009 Mar;11(3):292-8. doi: 10.1093/eurjhf/hfp001. Epub 2009 Jan 27.
7
From COPD to chronic systemic inflammatory syndrome?从慢性阻塞性肺疾病到慢性全身性炎症综合征？
Lancet. 2007 Sep 1;370(9589):797-9. doi: 10.1016/S0140-6736(07)61383-X.
8
Chronic obstructive pulmonary disease is underdiagnosed and undertreated in São Paulo (Brazil): results of the PLATINO study.慢性阻塞性肺疾病在巴西圣保罗地区存在诊断不足和治疗不足的情况：PLATINO研究结果
Braz J Med Biol Res. 2007 Jul;40(7):887-95. doi: 10.1590/s0100-879x2006005000133.
9
Mortality after an emergency department visit for exacerbation of chronic obstructive pulmonary disease.因慢性阻塞性肺疾病急性加重而到急诊科就诊后的死亡率。
COPD. 2006 Jun;3(2):75-81. doi: 10.1080/15412550600651271.
10
Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study.拉丁美洲五个城市的慢性阻塞性肺疾病（PLATINO研究）：一项患病率研究。
Lancet. 2005 Nov 26;366(9500):1875-81. doi: 10.1016/S0140-6736(05)67632-5.
Zotero 插件